The Biosimilar Approval Pathway: What Investors Need to Know

What a Biosimilar Is

A biosimilar is a biologic that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Because biologics are large, complex molecules made in living cells, a biosimilar can never be an identical copy the way a small-molecule generic is — hence "similar" rather than "same."

Biosimilars matter enormously to biotech investors because biologics make up a growing share of drug revenue, and biosimilar competition is the biologic equivalent of the patent cliff that has long pressured small-molecule franchises.

The 351(k) Pathway

Biosimilars are approved under an abbreviated pathway (section 351(k) of the Public Health Service Act) that lets a sponsor rely, in part, on the FDA's prior finding that the reference product is safe and effective. Instead of repeating the full clinical program, the biosimilar developer builds a case from:

• Analytical characterization — extensive structural and functional comparison to the reference biologic. This is the foundation.
• Nonclinical studies as needed.
• Targeted clinical studies, often including a comparative pharmacokinetic study and sometimes a confirmatory efficacy trial, to rule out meaningful differences.

The bar is "no clinically meaningful difference," demonstrated through this totality-of-evidence approach — not an independent demonstration of efficacy from scratch.

Interchangeability

A biosimilar can also seek interchangeable status, an additional FDA designation meaning it may be substituted for the reference product at the pharmacy without involving the prescriber, subject to state law. Interchangeability requires extra data, often including switching studies. For investors, interchangeability is commercially significant because it eases substitution and accelerates uptake.

Why Biosimilars Reshape Biotech Revenue

The arrival of biosimilar competition for a major reference biologic is a defining catalyst — usually a bearish one for the originator:

• Originator erosion. Biosimilars typically launch at a discount and erode the originator's revenue and pricing power, though more slowly than small-molecule generics erode brand sales.
• Patent-cliff timing. The timing hinges on patent expiry and litigation settlements, not just FDA approval. A biosimilar can be approved yet held off the market by patent protection on the reference product. Understanding a company's patent estate and exclusivity timelines is essential to modeling the cliff.
• New revenue for developers. For the biosimilar maker, approval opens a new revenue stream, though in an increasingly competitive, price-pressured category.

How Investors Should Analyze Biosimilar Exposure

When a company you follow has a major biologic franchise, map the biosimilar threat:

1. Which products face biosimilar competition, and when? Tie this to patent expiry and any litigation settlements that set a defined entry date.
2. How concentrated is revenue in the at-risk biologic? High concentration plus an approaching cliff is a valuation risk.
3. What is the pipeline replacement story? Originators defend against cliffs with next-generation products, new indications via supplemental applications, and lifecycle management.

For a biosimilar developer, the analysis flips: how many biosimilars are in development, what reference products do they target, and how crowded is each market?

Tracking the Catalysts

Biosimilar dynamics surface as FDA approval decisions, patent-expiry milestones, and the earnings updates where erosion first shows up. Track approval decisions on the catalyst calendar, monitor revenue trends through earnings, and review a company's biologic franchise and pipeline on its company page.

Biosimilars are where regulatory policy, patent law, and commercial strategy intersect. For investors, they turn a once-protected biologic franchise into a countdown — and create opportunity for the developers building the next wave of competition.